Health insurance assessment system for new drugs triggers debate

Published: 2008-04-25 06:58:00

Updated: 2008-04-25 06:58:00

The Health Insurance Review Agency's criteria to evaluate the effectiveness of anti-hyperlipemic agents in order to decide whether they are eligible for the list has been under fire as it could reduce the price of late players and thwart the development of new medicines, according to pharmaceutical business sources.

Recently, the agency announced that the price of Zocor will be maintaine...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.